BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus
Recruitment status was Recruiting
This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Patients undergoing an upper endoscopy will be asked to complete a gastroesophageal reflux disease (GERD) questionnaire, provide a blood sample and allow additional biopsies to be taken during the procedure.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Notch Signaling and Novel Biomarkers for Barretts Esophagus|
|Study Start Date:||November 2011|
|Estimated Study Completion Date:||November 2013|
|Estimated Primary Completion Date:||November 2013 (Final data collection date for primary outcome measure)|
With Barrett's Esophagus
Patients who have been diagnosed in the past with Barrett's Esophagus
Without Barrett's Esophagus
Patients without Barrett's Esophagus will be asked to take part so that comparison can be made with patients' tissue for those with the condition and those without the condition.
This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Currently there is very little understanding as to how Barrett's esophagus develops and why some people with Barrett's esophagus go on to develop esophageal cancer. The purpose of this study is to develop a better understanding of how these processes occur. The investigators also hope to use the information from this study to identify new molecular markers that the investigators can use to better determine who will or will not go on to develop esophageal cancer. Patients who have been diagnosed in the past with Barrett's esophagus will be asked to participate. Patients without Barrett's esophagus will be asked to take part so that the investigators can compare tissue from patients without the conditions to those with the conditions.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01484925
|Contact: Maureen DeMarshallfirstname.lastname@example.org|
|United States, Pennsylvania|
|Abramson Cancer Center||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Maureen DeMarshall 215-349-8546 email@example.com|
|Principal Investigator:||Gary Falk, MD||Abramson Cancer Center of the University of Pennsylvania|